^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    P013 (pertuzumab biosimilar)

    i
    Other names: P013
    Associations

    News

    Trials
    Company:
    CinnaGen
    Drug class:
    HER2 dimerization inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer (clinicaltrials.gov)
    P3, N=214, Completed, Cinnagen
    Clinical • New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • P013 (pertuzumab biosimilar)